

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of Rui Kang or China Wah Yan nor shall there be any sale, purchase or subscription for securities of Rui Kang or China Wah Yan in any jurisdiction in which such offer, solicitation or sale would be unlawful absent the filing of a registration statement or the availability of an applicable exemption from registration or other waiver. This announcement is not for release, publication or distribution in or into any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.



China Wah Yan Healthcare Limited

中國華仁醫療有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 648)



**RUI KANG PHARMACEUTICAL GROUP
INVESTMENTS LIMITED**

銳康藥業集團投資有限公司

*(Incorporated in the Cayman Islands and continued in
Bermuda with limited liability)*

(Stock Code: 8037)

**JOINT ANNOUNCEMENT
FURTHER DELAY IN DESPATCH OF CIRCULAR
AND
DELAY IN DESPATCH OF COMPOSITE DOCUMENT**

INTRODUCTION

Reference is made to (i) the joint announcement of China Wah Yan Healthcare Limited (“**China Wah Yan**”) and Rui Kang Pharmaceutical Group Investments Limited (“**Rui Kang**”) dated 17 February 2016 (the “**17 February Announcement**”) in relation to the voluntary conditional securities exchange offers by China Wah Yan to acquire all the issued shares in the capital of Rui Kang (other than those already owned by China Wah Yan and parties acting in concert with it) and cancel all outstanding share options of Rui Kang (the “**Offers**”); and (ii) the announcement of China Wah Yan dated 9 March 2016 in relation to the delay in despatch of the VSA Circular (as defined below) (the “**9 March Announcement**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the 17 February Announcement.

FURTHER DELAY IN DESPATCH OF CIRCULAR

As disclosed in the 9 March Announcement, the circular (the “**VSA Circular**”) containing, *inter alia*, further details of the Offers which constitutes the Very Substantial Acquisition, is expected to be despatched to the China Wah Yan Shareholders on or before 23 March 2016.

Since additional time is required for China Wah Yan to update and finalise certain information to be included in the VSA Circular, the date of despatch of the VSA Circular will be postponed to no later than 8 April 2016.

DELAY IN DESPATCH OF THE COMPOSITE DOCUMENT

Pursuant to Rule 8.2 of the Takeovers Code, the Composite Document is required to be despatched to the Rui Kang Shareholders and the Optionholders within 35 days after the date of the 17 February Announcement (i.e. on or before 23 March 2016).

Since additional time is required for China Wah Yan and Rui Kang to include in the Composite Document certain information, including the audited financial information of Rui Kang for the year ended 31 December 2015, which was published on 22 March 2016, and to update the disclosure in the Composite Document, the Composite Document will not be despatched within the time required under Rule 8.2 of the Takeovers Code. In this connection, an application has been made for, and the Executive has granted consent for, an extension of time for the despatch of the Composite Document to a date not later than 8 April 2016.

WARNING: The Share Offer is subject to the satisfaction or waiver (where applicable) of the conditions set out in the 17 February Announcement, and the Option Offer is subject to and conditional upon the Share Offer becoming or being declared unconditional in all respects. Accordingly, the Offers may or may not become unconditional. China Wah Yan Shareholders, Rui Kang Shareholders, Optionholders and potential investors of each of China Wah Yan and Rui Kang should therefore exercise caution when dealing in the securities of China Wah Yan and Rui Kang. Persons who are in doubt as to the action they should take should consult their stockbroker, bank manager, solicitor or other professional advisers.

By order of the board of directors of
China Wah Yan Healthcare Limited
CHAN Ka Chung
Chairman

By order of the board of directors of
Rui Kang Pharmaceutical Group
Investments Limited
LEUNG Pak Hou Anson
Executive Director

Hong Kong, 23 March 2016

The directors of China Wah Yan jointly and severally accept full responsibility for the accuracy of the information contained in this announcement, other than that relating to Rui Kang and the Rui Kang Group, and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this announcement (other than those expressed by Rui Kang and the Rui Kang Group) have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statements in this announcement misleading.

The directors of Rui Kang jointly and severally accept full responsibility for the accuracy of the information contained in this announcement, other than that relating to China Wah Yan and parties acting in concert with it, and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this announcement (other than those expressed by China Wah Yan and parties acting in concert with it) have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statements in this announcement misleading.

As at the date of this announcement, the board of directors of China Wah Yan comprises three executive directors, namely Mr. CHAN Ka Chung, Mr. CHEUNG Wai Kwan and Mr. WANG Jianguo; and three independent non-executive directors, namely, Mr. CHAN Yee Ping, Michael, Ms. HU Xuezheng and Mr. LAM Chun Ho.

As at the date of this announcement, the board of directors of Rui Kang comprises three executive directors, namely Mr. CHEUNG Hung (Chairman), Mr. LEUNG Pak Hou Anson and Ms. CHEN Miaoping (Chief Executive Officer); and three independent non-executive directors, namely Mr. YUEN Chun Fai, Mr. LEUNG Ka Fai and Mr. HO Fung Shan Bob.